MPP+

Industry leaders back plans for zero-emissions aluminium, ammonia and steel

Retrieved on: 
Wednesday, September 21, 2022
ETC, ArcelorMittal, Health, GHG, Budget, SSAB, Safety, Carbon, World Economic Forum, Aluminium, Policy, CSN, Recycling, SABIC, MPP+, BASF, Industry, Rio Tinto, Climate change, Aviation, ACWA Power, Steel, Thought, MPP, CEO, Technology, Hydrogen, EGA, Energy Transitions Commission, CF Industries, Ammonia, STS, Natural gas, Tata Steel, Emirates Global Aluminium, Climate Week NYC, Renewable energy, Risk management

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- More than 200 industry leaders have endorsed strategies from the Mission Possible Partnership (MPP) to decarbonise some of world's hardest-to-abate, carbon-intensive industries in this decade.

Key Points: 
  • Matt Rogers, CEO of MPP said: "These transition plans are operationally relevant and industry-backed, not wishful thinking or pie in the sky.
  • In the steel sector, early progress in breakthrough projects and increased supply of near-zero primary steel are essential to remain within a Paris-aligned sectoral carbon budget.
  • Sanjiv Paul, vice-president for safety, health and sustainability at Tata Steel, said: "This strategy has laid down the challenges for the steel industry to decarbonise.
  • MPP forecast demand for ammonia could increase six-fold by 2050, driven by new markets for green ammonia as a marine fuel and for power generation.

Industry leaders back plans for zero-emissions aluminium, ammonia and steel

Retrieved on: 
Wednesday, September 21, 2022
ETC, ArcelorMittal, Health, GHG, Budget, SSAB, Safety, Carbon, World Economic Forum, Aluminium, Policy, CSN, Recycling, SABIC, MPP+, BASF, Industry, Rio Tinto, Climate change, Aviation, ACWA Power, Steel, Thought, MPP, CEO, Technology, Hydrogen, EGA, Energy Transitions Commission, CF Industries, Ammonia, STS, Natural gas, Tata Steel, Emirates Global Aluminium, Climate Week NYC, Renewable energy, Risk management

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- More than 200 industry leaders have endorsed strategies from the Mission Possible Partnership (MPP) to decarbonise some of world's hardest-to-abate, carbon-intensive industries in this decade.

Key Points: 
  • Matt Rogers, CEO of MPP said: "These transition plans are operationally relevant and industry-backed, not wishful thinking or pie in the sky.
  • In the steel sector, early progress in breakthrough projects and increased supply of near-zero primary steel are essential to remain within a Paris-aligned sectoral carbon budget.
  • Sanjiv Paul, vice-president for safety, health and sustainability at Tata Steel, said: "This strategy has laid down the challenges for the steel industry to decarbonise.
  • MPP forecast demand for ammonia could increase six-fold by 2050, driven by new markets for green ammonia as a marine fuel and for power generation.

The Medicines Patent Pool (MPP) and MSD enter into licence agreement for molnupiravir, an investigational oral antiviral COVID-19 medicine, to increase broad access in low- and middle- income countries

Retrieved on: 
Wednesday, October 27, 2021
MSD, Safety, MPP+, Research, LinkedIn, Vaccine, Cancer, Industry, Government, Post-exposure prophylaxis, United Nations, Merck, Twitter, Security (finance), Medicine, U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, YouTube, SEC, Severe acute respiratory syndrome coronavirus 2, SDC, Life, Coronavirus, Merck & Co., Infection, Annual report, Patent, COVID-19, MPP, Animal, News, Medicines Patent Pool, Agency, Development, Unitaid, Population, Tuberculosis, HIV, Pharmaceutical industry

GENEVA, Oct. 27, 2021 /PRNewswire/ -- The Medicines Patent Pool (MPP) and MSD, the tradename of Merck & Co., Inc Kenilworth NJ USA, today announced the signing of a voluntary licencing agreement to facilitate affordable global access for molnupiravir, an investigational oral COVID-19 antiviral medicine. This agreement will help create broad access for molnupiravir use in 105 low- and middle-income countries (LMICs) following appropriate regulatory approvals.  MSD and Ridgeback Biotherapeutics are jointly developing molnupiravir.

Key Points: 
  • Molnupiravir has been shown to be active in several preclinical models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission.
  • The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
  • MPP's work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC).
  • The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

The Medicines Patent Pool (MPP) and MSD enter into licence agreement for molnupiravir, an investigational oral antiviral COVID-19 medicine, to increase broad access in low- and middle- income countries

Retrieved on: 
Wednesday, October 27, 2021
MSD, Safety, MPP+, Research, LinkedIn, Vaccine, Cancer, Industry, Government, Post-exposure prophylaxis, United Nations, Merck, Twitter, Security (finance), Medicine, U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, YouTube, SEC, Severe acute respiratory syndrome coronavirus 2, SDC, Life, Coronavirus, Merck & Co., Infection, Annual report, Patent, COVID-19, MPP, Animal, News, Medicines Patent Pool, Agency, Development, Unitaid, Population, Tuberculosis, HIV, Pharmaceutical industry

Molnupiravir has been shown to be active in several preclinical models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission.

Key Points: 
  • Molnupiravir has been shown to be active in several preclinical models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission.
  • The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
  • MPP's work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC).
  • The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.